Skip to Content
Merck
All Photos(1)

Documents

N0850000

Nimodipine

European Pharmacopoeia (EP) Reference Standard

Synonym(s):

1,4-Dihydro-2,6-dimethyl-4-(3-nitrophenyl)-3,5-pyridinedicarboxylic acid 2-methoxyethyl 1-methylethyl ester, Isopropyl 2-methoxyethyl 1,4-dihydro-2,6-dimethyl-4-(m-nitrophenyl)-3,5-pyridinedicarboxylate

Sign Into View Organizational & Contract Pricing
All Photos(1)

About This Item

Empirical Formula (Hill Notation):
C21H26N2O7
CAS Number:
66085-59-4
Molecular Weight:
418.44
MDL number:
MFCD00153848
UNSPSC Code:
41116107
PubChem Substance ID:
329818466
NACRES:
NA.24

grade

pharmaceutical primary standard

API family

nimodipine

manufacturer/tradename

EDQM

application(s)

pharmaceutical (small molecule)

format

neat

SMILES string

COCCOC(=O)C1=C(C)NC(C)=C(C1c2cccc(c2)[N+]([O-])=O)C(=O)OC(C)C

InChI

1S/C21H26N2O7/c1-12(2)30-21(25)18-14(4)22-13(3)17(20(24)29-10-9-28-5)19(18)15-7-6-8-16(11-15)23(26)27/h6-8,11-12,19,22H,9-10H2,1-5H3

InChI key

UIAGMCDKSXEBJQ-UHFFFAOYSA-N

Gene Information

human ... CACNA1C(775) , CACNA1D(776) , CACNA1F(778) , CACNA1S(779) , NR3C2(4306)

Looking for similar products? Visit Product Comparison Guide

General description

This product is provided as delivered and specified by the issuing Pharmacopoeia. All information provided in support of this product, including SDS and any product information leaflets have been developed and issued under the Authority of the issuing Pharmacopoeia.For further information and support please go to the website of the issuing Pharmacopoeia.

Application

Nimodipine EP Reference standard, intended for use in laboratory tests only as specifically prescribed in the European Pharmacopoeia.

Packaging

The product is delivered as supplied by the issuing Pharmacopoeia. For the current unit quantity, please visit the EDQM reference substance catalogue.

Other Notes

Sales restrictions may apply.

related product

Product No.
Description
Pricing

N0850010

Nimodipine impurity A, European Pharmacopoeia (EP) Reference Standard

1463870

Nimodipine Related Compound A, United States Pharmacopeia (USP) Reference Standard

1463858

Nimodipine, United States Pharmacopeia (USP) Reference Standard

1463869

Nimodipine Related Compound B, United States Pharmacopeia (USP) Reference Standard

Y0001784

Nimodipine for peak identification, European Pharmacopoeia (EP) Reference Standard

BP651

Nimodipine, British Pharmacopoeia (BP) Reference Standard

75161

Bis(1-methylethyl) 2,6-dimethyl-4-(3-nitrophenyl)-1,4-dihydropyridine-3,5-dicarboxylate, certified reference material, TraceCERT®, Manufactured by: Sigma-Aldrich Production GmbH, Switzerland

BP943

Nimodipine impurity A, British Pharmacopoeia (BP) Reference Standard

Pictograms

Exclamation mark
GHS07

Signal Word

Warning

Hazard Statements

H302

Precautionary Statements

P264 - P270 - P301 + P312 - P501

Hazard Classifications

Acute Tox. 4 Oral

Storage Class Code

11 - Combustible Solids

WGK

WGK 1

Flash Point(F)

Not applicable

Flash Point(C)

Not applicable

Choose from one of the most recent versions:

Certificates of Analysis (COA)

Lot/Batch Number

Sorry, we don't have COAs for this product available online at this time.

If you need assistance, please contact Customer Support.

Already Own This Product?

Find documentation for the products that you have recently purchased in the Document Library.

Visit the Document Library

J Horn et al.
Stroke, 32(10), 2433-2438 (2001-10-06)
Based on the results of animal experiments, clinical trials were performed with nimodipine, which did not demonstrate a beneficial effect on outcome after stroke. The aim of this study was to determine whether the evidence from animal experiments with nimodipine
W Mück et al.
Die Pharmazie, 49(2-3), 130-139 (1994-02-01)
The analytical test procedures currently established for the determination of the dihydropyridine calcium antagonist nimodipine in biological fluids are presented. Method of choice which has been dominantly used in pharmacokinetic investigations and drug interaction studies is gas chromatography with electron-capture
Potential interactions between nimodipine and adrenal hormones.
R L Isaacson et al.
Annals of the New York Academy of Sciences, 765, 134-142 (1995-09-15)
Mervyn D I Vergouwen et al.
The Lancet. Neurology, 5(12), 1029-1032 (2006-11-18)
Despite several randomised controlled trials, there is still much debate whether nimodipine improves outcome in patients with traumatic subarachnoid haemorrhage. A 2003 Cochrane review reported improved outcome with nimodipine in these patients; however, because the results of Head Injury Trial
Daniele Tomassoni et al.
Clinical and experimental hypertension (New York, N.Y. : 1993), 30(8), 744-766 (2008-11-21)
Nimodipine is a 1,4-dihydropyridine-derivative Ca(2+)-channel blocker developed approximately 30 years ago. It is highly lipophilic, crosses the blood-brain barrier, and reaches brain and cerebrospinal fluid. Early treatment with nimodipine reduces the severity of neurological deficits resulting from vasospasm in subarachnoid
View All Related Papers

Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.

Contact Technical Service